Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy - Wikidata - awgldk - TriplyDB

Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy

Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy

http://www.wikidata.org/entity/Q33624477

about

Rituximab for thyroid-associated ophthalmopathy Rituximab for thyroid-associated ophthalmopathy The evaluation and treatment of graves ophthalmopathy Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy.Rituximab in the Treatment of Thyroid Eye Disease: A Review Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab Correlation of HLA-DQ and TNF-α gene polymorphisms with ocular myasthenia gravis combined with thyroid-associated ophthalmopathy Update on thyroid-associated Ophthalmopathy with a special emphasis on the ocular surface Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: From bench to bedside.Randomized controlled trial of rituximab in patients with Graves' orbitopathy Rituximab therapy for refractory orbital inflammation: results of a phase 1/2, dose-ranging, randomized clinical trial.Rituximab (Rituxan) therapy for severe thyroid-associated ophthalmopathy diminishes IGF-1R(+) T cells Rituximab in refractory Vogt-Koyanagi-Harada disease.Ocular changes and approaches of ophthalmopathy in basedow - graves- parry- flajani disease.Efficacy of Subantimicrobial Dose Doxycycline for Moderate-to-Severe and Active Graves' Orbitopathy.The pathophysiology of thyroid eye disease: implications for immunotherapy.The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy Thyroid associated orbitopathy: Understanding pathophysiology.Thyroid-associated orbitopathy: Current insights into the pathophysiology, immunology and management.Clinical efficacy of combined rituximab treatment in a woman with severe Graves' ophthalmopathy Efficacy and Complications of Intravitreal Rituximab Injection for Treating Primary Vitreoretinal Lymphoma Graves' orbitopathy: imperfect treatments for a rare disease.Rituximab Treatment in a Patient with Active Graves' Orbitopathy and Psoriasis.Pathogenesis of Graves' orbitopathy: a 2010 update.Thyroid eye disease: towards an evidence base for treatment in the 21st century New biologic-response modifiers in ocular inflammatory disease: beyond anti-TNF treatment.Medical management of thyroid eye disease.The expanding role of therapeutic antibodies.Treatment modalities of thyroid related orbitopathy.Dysthyroid Orbitopathy Presenting with Gaze-Evoked Amaurosis: Case Report and Review of the Literature.Advances in the pharmacological treatment of Graves' orbitopathy.Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management.Rituximab therapy in steroid-resistant severe hypothyroid Grave's ophthalmopathy.Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysis.The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves' orbitopathy.The Efficacy of Rituximab Combined with 131I for Ophthalmic Outcomes of Graves' Ophthalmopathy Patients.Orbital decompression for thyroid-associated orbitopathy in England: trends over time and geographical variation.

P2860

Q24202845-0CEB7515-ECC4-433E-93ED-F633670889DC Q24235160-9018CABA-701E-4D5A-B1D7-09DF6E92B1ED Q26862144-B93BA7DD-1027-4216-AE76-34EFD84EEF4A Q27691806-701B55CC-D25C-4152-947D-CCAB962266BD Q28081573-F03F1EBE-342A-4EBB-9169-D2369ED85E26 Q33741009-A9B01BAC-1176-40CE-92E9-8E4958C923C0 Q33792654-356FCBF2-937D-4E32-BD61-E521D3730866 Q33802192-4C135A85-AFEC-490A-9DAB-BAB58AF92337 Q34763844-5AAC88D4-4578-47E2-B88E-AF865F17293E Q35055124-DC30B426-BA3A-4AC2-BFD1-C492AA5ED764 Q35064588-BC222A7C-9124-4FCF-A9EF-38BCC155FAFD Q35443741-CEC2AE31-EF0B-481F-8108-206DDC4C9A44 Q35571023-757FE3B3-1A06-4170-BA5E-AA0F73B1C48B Q35617803-F0C69BAC-5C0B-4FEC-87AD-515679165E44 Q35843863-9BEFB659-136B-4952-A380-DD47681AE9D1 Q36439938-3BE02D17-D16E-4D63-A6AE-86B350759B15 Q36811289-54E96727-8BE3-463C-B4D6-8497B363F0D8 Q37059979-D1E1A50A-672E-4FDE-B811-378AFC8E3FC3 Q37060528-FC772E0D-CD4F-4C78-A220-F4E72D015C92 Q37106626-1E75B3F2-FE7C-4657-A17E-D1370FDEF1B9 Q37149388-141A698A-4333-4E12-BC67-7A8C5631F626 Q37582446-13D00B77-CFD7-46F8-87AF-D454CDCED46F Q37615281-5C9B35EB-C0E1-4C9C-8BB5-E72FE2C6E80D Q37772737-C3BF2763-5AC8-4F32-81CE-3660F420B45F Q37987063-FEB01554-172A-49BE-A5D8-459A488D16EE Q38057370-B0FE5F51-8D85-4674-80FC-4EE83395D416 Q38130235-13B202B8-BDAC-4625-90B3-65BD7F524BAE Q38182645-CB8E7D6D-4E69-4A02-BE8D-393D697CF747 Q38275638-56FBEF33-D52D-4BD8-8E9C-37C185947504 Q38617080-FD62F320-2FDA-4B61-AC57-F55F56C4782B Q38769722-8A3CFA51-7EFF-418B-821B-9D237BF17E12 Q40095263-27FD2CCB-D8C0-4BD2-BC63-8010AA8B608E Q42156384-15C4F8C0-FAC0-4EAD-AEBE-9933977AA7CD Q43042591-18F5D6E2-33AD-4E99-9BF5-0EBF7A1D88D1 Q49920960-0D149192-14E8-4A7B-AFD8-EA941E981697 Q50795971-E3602E6B-E387-4275-806D-8ACDEE296DCC Q51220468-B6A400F0-39C4-48E2-B5EC-68BCD4C0B48D Q51232684-83A0E830-A651-4F67-A387-9B33872E85E6

P2860

Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy

http://www.wikidata.org/entity/Q33624477

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

Rituximab treatment of patient ...... roid-associated ophthalmopathy

@ast

Rituximab treatment of patient ...... roid-associated ophthalmopathy

@en

type

label

Rituximab treatment of patient ...... roid-associated ophthalmopathy

@ast

Rituximab treatment of patient ...... roid-associated ophthalmopathy

@en

prefLabel

Rituximab treatment of patient ...... roid-associated ophthalmopathy

@ast

Rituximab treatment of patient ...... roid-associated ophthalmopathy

@en

P1433

Q33624477-E4DD9DE1-292A-4616-BD0F-3A784847E323

P1476

Q33624477-ABB8866D-CA6B-4D54-AC89-241EC21E9B64

P2093

Q33624477-0ECF9D97-A5D0-4440-8CCA-24E996F22AB4

Q33624477-42F5EDDF-D1F2-4186-A0A4-F66E049145C7

Q33624477-72BD919B-F7E6-4A8B-A12F-3B242A67C185

Q33624477-8E1623FA-C907-4682-841E-6E4F61B70DF8

Q33624477-A89462A2-5F9C-4F60-B9F5-7E157A8F02D8

Q33624477-ABA17303-6632-4A6F-92B7-DA31608253F8

Q33624477-B77142EB-FD27-4A2E-B3BE-02FADF1A53F3

P2860

Q33624477-04D35BBE-18F5-42C8-9092-1BBF95B4F3A2

Q33624477-068707C8-514E-467B-919D-FA05D93BF470

Q33624477-074C7F04-E174-4846-8962-51B30E0F6C49

Q33624477-078BA6B5-415C-4EC6-AC22-97908AED9C3E

Q33624477-10D530BF-5183-4E2F-9F14-B9D774EB294D

Q33624477-19B2BD05-CBE7-4B4E-8CB4-226400A992B8

Q33624477-2592E62B-4182-4E58-B2A3-7846B1F07837

Q33624477-2A5D42FB-3663-4D4D-B26B-9E4FE13653FA

Q33624477-2D8F6753-93D8-48A1-9ACF-D71C7E5F3812

Q33624477-3625E699-0688-43AC-88D2-6482D4202443

P304

Q33624477-23895D03-0F06-4205-BFD9-3C819CA6C334

P31

Q33624477-30B2D9D5-E61B-4628-BDE2-9E3FBF94A80D

P356

Q33624477-7D2F1702-A0DD-4E71-89B8-BAC1E6326641

P433

Q33624477-C89962C1-8FF5-4A0E-919E-D1CDC5C756B3

P478

Q33624477-549372DE-FA68-4386-AA11-169AA528687C

P50

Q33624477-7978C50B-80E0-45B2-B620-7DDDF12B0419

Q33624477-E9C2A18A-34E6-4EE5-ACBD-26F12C91CCCC

Q33624477-E9CA1E58-CC6A-4F03-905E-4C1A43AF33C9

P577

Q33624477-CD139752-B838-474E-863B-ED7977EAD46D

P5875

Q33624477-B5FF5EFF-A5BA-4666-9220-0627C25EB702

P698

Q33624477-A7D4A41C-AC69-4942-9750-FDF4814AA40E

P932

Q33624477-B78DA392-157A-4560-9E71-3717060E962D

P356

J.OPHTHA.2009.05.029

P1433

P1476

Rituximab treatment of patient ...... roid-associated ophthalmopathy

@en

P2093

Catherine J Hwang

http://www.w3.org/2001/XMLSchema#string

Christine H Darwin

http://www.w3.org/2001/XMLSchema#string

Diana K Lee

http://www.w3.org/2001/XMLSchema#string

Dinesh Khanna

http://www.w3.org/2001/XMLSchema#string

Helene Chokron Garneau

http://www.w3.org/2001/XMLSchema#string

Nikoo F Afifiyan

http://www.w3.org/2001/XMLSchema#string

Robert A Goldberg

http://www.w3.org/2001/XMLSchema#string

P2860

How regulatory T cells work

Clinical manifestations and treatment outcome of optic neuropathy in thyroid-related orbitopathy.

NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis.

Epidemiology and estimated population burden of selected autoimmune diseases in the United States.

Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach.

From T to B and back again: positive feedback in systemic autoimmune disease.

An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.

Consensus statement on the use of rituximab in patients with rheumatoid arthritis

The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option.

B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family.

P304

133-139.e2

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.OPHTHA.2009.05.029

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

Raymond S Douglas

P577

2009-10-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26884272

http://www.w3.org/2001/XMLSchema#string

P698

19818507

http://www.w3.org/2001/XMLSchema#string

P932

2814962

http://www.w3.org/2001/XMLSchema#string